Contact Us Print

Alvogen in brief

Alvogen is a multinational, privately-owned pharmaceuticals company focused on complex generic pharmaceuticals products. The company is committed to building a next-generation generics company through the strategic selection of products, partners and markets, and the utilization of an effective consolidated global supply chain.

Alvogen is built on the strong foundation of Norwich Pharmaceuticals in New York. With a 120 year history and an unsurpassed regulatory track record Norwich is committed to continuous improvement and delivering exceptional value to all stakeholders. The company aims to produce only high quality products and services, on time, every time. The Norwich plant, with an annual capacity of five billion tablets and capsules, is the US manufacturing base of Alvogen.

Corporate Headquarters are in Pinebrook, New Jersey. With offices in over 20 countries, Alvogen’s key markets include; North America, Hungary, Romania, Bulgaria, the Balkans, China, Thailand and Taiwan. Contact customer service in individual offices to learn about local and regional product offering.


A world-class team with a proven track record leads Alvogen’s global expansion. In July 2009, Alvogen unveiled its plans to become a top ten generic pharmaceuticals company over the course of the next five years. Robert Wessman, former CEO of Actavis Group, is Alvogen's Chairman & CEO  and will lead the company's global expansion. Alvogen has assembled an international team of exceptional people with global and local expertise, who are committed to creating a leader in pharmaceuticals. 


Targeted selection of products and markets

Alvogen has more than 200 pharmaceutical products in development and registration, with over 80 products expected to be launched in 2011. The group´s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has first-class regulatory, development and manufacturing capabilities in Asia, Europe and North America.

  • We focus on difficult to make and high value formulations and pursue first-to-file opportunities. Our product pipeline will be filled by selections from internal R&D candidates, in-licensed products, fostering strategic partnerships and targeted portfolio acquisitions.
  • We work collaboratively and strive to build a dependable network of partners around the world to support manufacturing, product development, supply chains and sales.
  • We strategically select our markets, with special focus on high-growth areas. Our marketing network is built around greenfield operations, partnerships and strategic acquisitions, based on market intelligence.



Our organizational culture

Alvogen is not a conventional company, and we don’t intend to become one. We are not afraid to follow the unbeaten path in our efforts to differentiate, provide innovative solution to our customers and drive our business forward. We have defined an ambitious strategic roadmap to guide us towards our goal to become a top ten globa genericsl player by 2015 - and we will have fun doing it.

We are energetic and creative, always seeking to improve. We learn from our successes and failures and we always encourage and support new ideas. We believe that by rethinking generics and challenging current industry norms we can create the pharmaceutical company of tomorrow. With a radical new business model, we are dedicated to enhancing quality of life and delivering exceptional value to all our stakeholders. We do so by being change-driven, passionate, innovative and always customer focused – this is the drive we look for in our people.

Alvogen has offices around the world, from Bangalore to Bulgaria, but regardless of where we are, we nurture our values and positive working environment by hiring street-smart, innovative, local people who share our competitive spirit and passion to stand out and succeed.


great_adventure

Strategy 2015

  • In July 2009, Alvogen unveiled its plans to substantially grow the company globally and to become a top ten generic pharmaceuticals player over the course of the next five years. Robert Wessman, former CEO of Actavis Group, is the Chairman & CEO and leads Alvogen´s global expansion.  The reality facing the generic pharmaceutical industry today is a continuous decline towards a purely commodity-based business, creating tremendous pressures on operating costs.
  • The future of a successful generic pharmaceuticals company rests on becoming a lean, flexible, multinational operation that overcomes the challenges of the traditional generic business model. History has taught us that challenging times create real opportunities for change – new ideas and new approaches.
  • We are rethinking generics, with a radical new business model that creates the pharmaceutical company of tomorrow.
  • Our employees have an inherent thirst for change that is clearly visible in our business model, processes and actions. Like athletes, inventors and explorers before us, we know that there can always be a better way to do things, if only we dare to challenge the status quo and rethink the future.